Enobosarm ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) (also known as Ostarine GTx-024 and MK-2866) is an investigational selective androgen receptor modulator (SARM) from GTX Inc for treatment of conditions such as muscle wasting and osteoporosis formerly under development by Merck & Company.
This page contains content from the copyrighted Wikipedia article "Enobosarm"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
